|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29 (Suppl 4):iv192–iv237. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dearden S, Stevens J, Wu YL and Blowers D:
Mutation incidence and coincidence in non small-cell lung cancer:
Meta-analyses by ethnicity and histology (mutMap). Ann Oncol.
24:2371–2376. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Koivunen JP, Mermel C, Zejnullahu K,
Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas
R, et al: EML4-ALK fusion gene and efficacy of an ALK kinase
inhibitor in lung cancer. Clin Cancer Res. 14:4275–4283.
2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Rikova K, Guo A, Zeng Q, Possemato A, Yu
J, Haack H, Nardone J, Lee K, Reeves C, Li Y, et al: Global survey
of phosphotyrosine signaling identifies oncogenic kinases in lung
cancer. Cell. 131:1190–1203. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Takeuchi K, Choi YL, Togashi Y, Soda M,
Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y, et al:
KIF5B-ALK, a novel fusion oncokinase identified by an
immunohistochemistry-based diagnostic system for ALK-positive lung
cancer. Clin Cancer Res. 15:3143–3149. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Zhang S, Anjum R, Squillace R, Nadworny S,
Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, et al: The
potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of
resistance to first- and second-generation ALK inhibitors in
preclinical models. Clin Cancer Res. 22:5527–5538. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shi Y, Chen J, Zhang H, Zhang Z, Zhang Y,
Wang Z, Zhang S, Zhao J, Liu C, Wang X, et al: Efficacy and safety
of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant
advanced non-small cell lung cancer patients: A single-arm,
multicenter phase II study (INTELLECT). BMC Med.
21(72)2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Yang JCH, Ou SHI, De Petris L, Gadgeel S,
Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, et
al: Pooled systemic efficacy and safety data from the pivotal phase
II studies (NP28673 and NP28761) of alectinib in ALK-positive
non-small cell lung cancer. J Thorac Oncol. 12:1552–1560.
2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wolf J, Helland Å, Oh IJ, Migliorino MR,
Dziadziuszko R, Wrona A, de Castro J, Mazieres J, Griesinger F,
Chlistalla M, et al: Final efficacy and safety data, and
exploratory molecular profiling from the phase III ALUR study of
alectinib versus chemotherapy in crizotinib-pretreated ALK-positive
non-small-cell lung cancer. ESMO Open. 7(100333)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yang JCH, Liu G, Lu S, He J, Burotto M,
Vincent S, Yin J, Ma X and Popat S: 319O ALTA-3: A randomized trial
of brigatinib (BRG) vs alectinib (ALC) in crizotinib
(CRZ)-refractory advanced ALK+ NSCLC. Ann Oncol. 33(S1564)2022.
|
|
14
|
Gettinger SN, Huber RM, Kim DW, Bazhenova
L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL,
Reckamp KL, et al: Long-term efficacy and safety of brigatinib in
crizotinib-refractory ALK+ NSCLC: Final results of the phase 1/2
and randomized phase 2 (ALTA) trials. JTO Clin Res Rep.
3(100385)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Dickson BC, Swanson D, Charames GS,
Fletcher CD and Hornick JL: Epithelioid fibrous histiocytoma:
Molecular characterization of ALK fusion partners in 23 cases. Mod
Pathol. 31:753–762. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen YL, Chen WL, Cheng YC, Lin MC, Yang
SC, Tsai HW, Lin CC, Su WC, Chow NH and Ho CL: Development of a
novel ALK rearrangement screening test for non-small cell lung
cancers. PLoS One. 16(e0257152)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ma L, Zhang Q, Dong Y, Li H and Wang J:
SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in
non-small cell lung cancer. Lung Cancer. 143:97–100.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982.PubMed/NCBI
|
|
20
|
Wen PY, Macdonald DR, Reardon DA,
Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert
MR, Lassman AB, et al: Updated response assessment criteria for
high-grade gliomas: Response assessment in neuro-oncology working
group. J Clin Oncol. 28:1963–1972. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
National Cancer Institute. Common
terminology criteria for adverse events (CTCAE). 2010. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
Accessed October 31, 2023.
|
|
22
|
Bagchi A, Orr BA, Campagne O, Dhanda S,
Nair S, Tran Q, Christensen AM, Gajjar A, Furtado LV, Vasilyeva A,
et al: Lorlatinib in a child with ALK-fusion-positive high-grade
glioma. N Engl J Med. 385:761–763. 2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chiarle R, Voena C, Ambrogio C, Piva R and
Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of
cancer. Nat Rev Cancer. 8:11–23. 2008.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Shaw AT, Kim TM, Crinò L, Gridelli C,
Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, et al:
Ceritinib versus chemotherapy in patients with ALK-rearranged
non-small-cell lung cancer previously given chemotherapy and
crizotinib (ASCEND-5): A randomised, controlled, open-label, phase
3 trial. Lancet Oncol. 18:874–886. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wu YL, Shi Y, Tan DSW, Xiaoqing L, Cheng
Y, Zhou J, An TT, Lu Y, Zhu B, Bai C, et al: Phase 1/2 study of
ceritinib in Chinese patients with advanced anaplastic lymphoma
kinase-rearranged non-small cell lung cancer previously treated
with crizotinib: Results from ASCEND-6. Lung Cancer. 150:240–266.
2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yang Y, Zhou J, Zhou J, Feng J, Zhuang W,
Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, et al: Efficacy, safety,
and biomarker analysis of ensartinib in crizotinib-resistant,
ALK-positive non-small-cell lung cancer: A multicentre, phase 2
trial. Lancet Respir Med. 8:45–53. 2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Liu X, Zhang L, Wan H, Zhu Z, Jin J, Qin
Y, Mao W, Yan K, Fang D, Jiang W, et al: Discovery and preclinical
evaluations of WX-0593, a novel ALK inhibitor targeting
crizotinib-resistant mutations. Bioorg Med Chem Lett.
66(128730)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Shi Y, Fang J, Hao X, Zhang S, Liu Y, Wang
L, Chen J, Hu Y, Hang X, Li J, et al: Safety and activity of
WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged
advanced non-small cell lung cancer: A phase 1 dose-escalation and
dose-expansion trial. Signal Transduct Target Ther.
7(25)2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yang Y, Zheng Q, Wang X, Zhao S, Huang W,
Jia L, Ma C, Liu S, Zhang Y, Xin Q, et al: Iruplinalkib (WX-0593),
a novel ALK/ROS1 inhibitor, overcomes crizotinib resistance in
preclinical models for non-small cell lung cancer. Invest New
Drugs. 41:254–266. 2023.PubMed/NCBI View Article : Google Scholar
|
